Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation. Issue 10 (24th August 2019)

• Record Type: Journal Article
• Authors: Beyar-Katz, Ofrat; Lavi, Noa; Ringelstein-Harlev, Shimrit; Henig, Israel; Yehudai-Ofir, Dana; Haddad, Nuhad; Fineman, Riva; Ofran, Yishai; Nov, Yuval; Sahar, Dvora; Moustafa-Hawash, Nivin; Rowe, Jacob M.; Zuckerman, Tsila
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 10(2019)
• Page Start: 2449
• Page End: 2456
• Publication Date: 2019-08-24
• Subjects: Acute myeloid leukemia (AML) -- autologous SCT (ASCT) -- core-binding factor (CBF) translocation -- NPM1 mutation; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1594214
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18 – inv(16). Forty patients received chemotherapy alone, 26 underwent ASCT upfront. In time-dependent analysis, the ASCT group demonstrated higher relapse-free (RFS) ( p = .001) and overall survivals (OS) ( p = .0007). The 1-year RFS and OS were 44.2% vs 88% and 71% vs 96% for chemotherapy and ASCT, respectively. The corresponding TRM was 4/40 (10.0%) and 0/26 (0%), with relapse rates of 70.0% and 19.2% ( p = .0002). In multivariate analysis, ASCT was associated with superior OS and RFS. In conclusion, ASCT offers significantly superior RFS and OS in favorable-risk AML in first complete remission. These data support the recent resurgence of interest in ASCT for AML.